Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.Pfizer expects to have the website up before the end of this year.

在礼来公司（Eli Lilly）的带领下，辉瑞将建立一种直接面向消费者的服务，在网上销售一些药物，避免行业中间商。该公司向英国《金融时报》表示，该公司计划以这种方式销售新型冠状病毒治疗剂Paxlovid和偏头痛鼻喷雾剂等产品。辉瑞公司预计该网站将于今年年底前上线。

It will connect patients with consultants to prescribe the drugs, with a supplier filling and shipping the prescriptions, sources told FT.In the case of Lilly—which launched LillyDirect in January to offer home delivery of diabetes, obesity and migraine medications—the company uses Amazon Pharmacy and Truepill as its third-party distributors.The moves are part of a broader effort in the industry to simplify the distribution of products—especially those in high demand such as obesity treatments—and to cut costs associated with going through middlemen.During its first quarter earnings report, which Pfizer provided on Wednesday, it did not address its new direct-to-consumer service.Pfizer reported revenue of $14.9 billion for the first quarter.

消息人士告诉英国《金融时报》，它将让患者与顾问联系开药，并由供应商填写和运输处方。就礼来而言，礼来公司于1月份推出了LillyDirect，提供糖尿病、肥胖症和偏头痛药物的家庭配送，该公司使用亚马逊药房和Truepill作为其第三方分销商。这些举措是该行业更广泛努力的一部分，旨在简化产品的分销，尤其是那些需求量较大的产品，如肥胖症治疗，并降低与通过中间商相关的成本。辉瑞（Pfizer）周三提供的第一季度盈利报告中，没有提及其新的直接面向消费者服务。辉瑞第一季度收入149亿美元。

It was a 20% drop in sales, which made it the fifth straight quarter that the company saw a year-over-year decrease. On the plus side however, it was the third straight quarter that Pfizer saw a sequential increase in revenue—from $12.7 billion in the second quarter of 2023, to $13.2 billion in the third quarter and $14.2 billion in the fourth quarter.The first quarter figure also surprised analysts (Zacks, FactSet) who estimated revenue to come in at $13.9 billion and helped propel a stock surge as price of shares increased 4% by late-morning, a positive reversal considering shares had fallen 10% this year and 34% over the previous 12 months.Sales of Pfizer’s COVID products Co.

销售额下降了20%，这是该公司连续第五个季度同比下降。然而，从好的方面来看，辉瑞公司的收入连续第三个季度从2023年第二季度的127亿美元增长到第三季度的132亿美元和第四季度的142亿美元。第一季度的数字也令分析师（Zacks，FactSet）感到惊讶，他们估计收入将达到139亿美元，并推动了股价飙升，因为截至上午晚些时候，股价上涨了4%，考虑到今年股价下跌了10%，过去12个月下跌了34%，这是一个积极的逆转。辉瑞公司新型冠状病毒产品公司的销售。